Search PubMed⌕ Search

Biomedical subjects

P B Agrawal

Publications and source records attributed to P B Agrawal.

3 recordsLinked to original sources

Epidemiology of systemic candidiasis in a tertiary care neonatal unit.

143 neonates were diagnosed to have acquired systemic candidiasis out of a total 4530 admissions (3.2 per cent) to the neonatal intensive care unit (NICU) during a period of 6 1/2 years from January 1990 to June 1996. Mean age at onset was 10.4 days, mean birth weight 1454 g, and mean gestation was 31.7 weeks. Ninety-four per cent were premature, 95 per cent low birth weight (LBW), and all had undergone peripheral vein catheterization and had received broad spectrum antibiotics, except one, prior to the diagnosis. Fifty-eight per cent were ventilated and 15 per cent received parenteral nutrition. Persistent/recurrent pneumonia, apnoea, lethargy, high gastric aspirates, and abdominal distension were the common clinical manifestations. Candida tropicalis, C. albicans, and C. guillermondii were the most common isolates. Blood and urine were the predominant sites for isolation of Candida. Fluconazole was the most used antifungal agent, with 24 per cent resistance against it. Fifty per cent of babies died due to all causes. Of all the deaths, two-thirds were Candida related. Candida-attributable deaths occurred in 24 cases (17 per cent).

Age of Onset↗

Host factors and pneumonia in hospitalised children.

Acute respiratory infections (ARI) account for 20-24% of childhood deaths in India. The present study investigated the host related risk factors in the outcome of pneumonia in 127 hospitalised children between the ages of 2 months and 5 years. The case fatality rate in the study was 11.8%. Presence of malnutrition is a significantly important factor for both increased duration of pneumonia and fatal outcome. Other factors for increased pneumonia mortality include the presence of associated illness and the severity of the pneumonia.

Age Factors↗

Fluconazole.

Incidence of systemic candidiasis is increasing with improvement in the survival of high risk neonates who undergo multiple interventions. Therapies available to treat systemic fungal infection are few and have several drawbacks. Fluconazole, a new triazole derivative may be a useful anti-fungal agent in view of its excellent oral absorption, easy administration, low plasma protein affinity, long half-life, high concentrations in urine and CSF, minimal adverse reactions, wide spectrum of anti-fungal activity and high specificity for fungal cytochrome P450 system. Its utility in neonates and children with candidiasis has already been documented by few case reports and studies.

Antifungal Agents↗